On May 21, 2021 Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, reported a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Meeting, which will be held from June 4-8, 2021 (Press release, Lantheus Medical Imaging, MAY 21, 2021, View Source [SID1234580454]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will be made available for the duration of conference.
Details for the ASCO (Free ASCO Whitepaper) presentation are as follows:
Session Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile
Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval
Abstract No: 5023